Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 10/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | BUB1 | O43683 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26128976 | 0.87 | DRD4 (0.46) | EPHA2EPHB4KDRDRD4IRAK4 | |
| SCHEMBL30613625 | 0.84 | EPHA2 (0.49) | EPHA2EPHB4ERBB2KDRRET | |
| SCHEMBL30613661 | 0.84 | EPHA2 (0.48) | EPHA2EPHB4ERBB2KDRRET | |
| SCHEMBL30613668 | 0.84 | EPHA2 (0.48) | EPHA2EPHB4ERBB2KDRRET | |
| SCHEMBL30613621 | 0.81 | EPHA2 (0.46) | EPHA2EPHB4ERBB2RETBUB1 | |
| SCHEMBL30613657 | 0.81 | EPHA2 (0.46) | EPHA2EPHB4ERBB2KDRRET | |
| SCHEMBL30613620 | 0.81 | EPHA2 (0.46) | EPHA2EPHB4ERBB2RETBUB1 | |
| SCHEMBL30613693 | 0.81 | EPHA2 (0.46) | EPHA2EPHB4ERBB2RETBUB1 | |
| SCHEMBL13482977 | 0.81 | EPHA2 (0.54) | EPHA2EPHB4ERBB2BUB1POLB | |
| SCHEMBL4510923 | 0.79 | EPHA2 (0.54) | EPHA2EPHB4ERBB2RETDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
| EP-4504724-A1 | SPLEEN TYROSINE KINASE INHIBITORS | Uniquest Pty Limited (AU) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023193054-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | EPHA2 1019/4885EPHB4 1421/4885ERBB2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.